HEARTFLOW INC (HTFL) — insider trading
Health Care · NASDAQ
HEARTFLOW INC (HTFL) has 20 reported SEC Form 4 insider transactions in our data, including 4 open-market sales among the most recent 20 (latest 2026-07-15).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-15 | Rogers Campbell | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 9,219 | $0.00 | $0 | Form 4 |
| 2026-07-15 | Rogers Campbell | Officer (Chief Medical Officer) | Open-market sale | 9,219 | $25.72 | $237.1K | Form 4 |
| 2026-07-15 | Rogers Campbell | Officer (Chief Medical Officer) | Option exercise / conversion | 9,219 | $19.00 | $175.2K | Form 4 |
| 2026-07-10 | Farquhar John C.M. | Director, Officer (Chief Executive Officer) | Open-market sale | 22,562 | $27.75 | $626.1K | Form 4 |
| 2026-07-08 | WELDON WILLIAM C | Director | Option exercise / conversion (derivative) | 17,123 | $0.00 | $0 | Form 4 |
| 2026-07-08 | WELDON WILLIAM C | Director | Option exercise / conversion (derivative) | 17,123 | $0.00 | $0 | Form 4 |
| 2026-07-08 | WELDON WILLIAM C | Director | Option exercise / conversion (derivative) | 17,123 | $0.00 | $0 | Form 4 |
| 2026-07-08 | WELDON WILLIAM C | Director | Option exercise / conversion | 17,123 | $8.33 | $142.6K | Form 4 |
| 2026-07-08 | WELDON WILLIAM C | Director | Option exercise / conversion | 17,123 | $8.33 | $142.6K | Form 4 |
| 2026-07-08 | WELDON WILLIAM C | Director | Option exercise / conversion | 17,123 | $8.33 | $142.6K | Form 4 |
| 2026-06-24 | Farquhar John C.M. | Director, Officer (Chief Executive Officer) | Open-market sale | 38,900 | $35.00 | $1.36M | Form 4 |
| 2026-06-16 | Tansey Casey M | Director | Grant / award / vesting (derivative) | 16,075 | $32.05 | $515.2K | Form 4 |
| 2026-06-16 | Riley Wayne Joseph | Director | Grant / award / vesting (derivative) | 16,075 | $32.05 | $515.2K | Form 4 |
| 2026-06-16 | Lightcap Jeffrey C | Director | Grant / award / vesting (derivative) | 16,075 | $32.05 | $515.2K | Form 4 |
| 2026-06-16 | Cullivan Julie A | Director | Grant / award / vesting (derivative) | 16,075 | $32.05 | $515.2K | Form 4 |
| 2026-06-16 | BARABE TIMOTHY C | Director | Grant / award / vesting (derivative) | 16,075 | $32.05 | $515.2K | Form 4 |
| 2026-06-16 | WELDON WILLIAM C | Director | Grant / award / vesting (derivative) | 16,075 | $32.05 | $515.2K | Form 4 |
| 2026-06-15 | Rogers Campbell | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 10,000 | $0.00 | $0 | Form 4 |
| 2026-06-15 | Rogers Campbell | Officer (Chief Medical Officer) | Option exercise / conversion | 10,000 | $2.22 | $22.2K | Form 4 |
| 2026-06-10 | Farquhar John C.M. | Director, Officer (Chief Executive Officer) | Open-market sale | 22,562 | $28.50 | $643.0K | Form 4 |
Ask the chat about HTFL's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: HEARTFLOW INC (HTFL).
Last updated 2026-07-15 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.